Literature DB >> 3168961

Compliance during treatment of epilepsy.

I E Leppik1.   

Abstract

Noncompliance is a major factor in suboptimal control of epileptic seizures. As many as one-third to one-half of persons with epilepsy may be noncompliant. Noncompliance negates the usefulness of the advances made in the diagnosis and treatment of epilepsy and is perhaps the single most important factor in increasing the costs of care for people with epilepsy. Although the issue of noncompliance is very complex, realization that it is a multidimensional problem and varies from patient to patient should help individualize its evaluation and approach. Noncompliance can be described by three dimensions: behavior, extent, and intentionality. The simplest methods for determining noncompliance are measurements of the antiepileptic drug concentration and patient interview. Calculation of a coefficient of variation for serial anticonvulsant drug levels may be more descriptive, however. Education and devices to simplify dosing are the primary strategies for improving compliance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168961     DOI: 10.1111/j.1528-1157.1988.tb05801.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

Review 1.  Compliance aids--do they work?

Authors:  P H Rivers
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 2.  Concentration-controlled trials. What does the future hold?

Authors:  A Johnston; D W Holt
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 3.  Care of patients with epilepsy in the community: will new initiatives address old problems?

Authors:  A K Thapar
Journal:  Br J Gen Pract       Date:  1996-01       Impact factor: 5.386

4.  Noncompliance with Treatment of Neurologic Disease.

Authors:  Jeffrey S. Nicholl
Journal:  Curr Treat Options Neurol       Date:  2002-11       Impact factor: 3.598

5.  A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors.

Authors:  Adam S Wu; Victoria T Trinh; Dima Suki; Susan Graham; Arthur Forman; Jeffrey S Weinberg; Ian E McCutcheon; Sujit S Prabhu; Amy B Heimberger; Raymond Sawaya; Xuemei Wang; Wei Qiao; Kenneth Hess; Frederick F Lang
Journal:  J Neurosurg       Date:  2013-02-08       Impact factor: 5.115

Review 6.  The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies.

Authors:  Caroline K Mbuba; Anthony K Ngugi; Charles R Newton; Julie A Carter
Journal:  Epilepsia       Date:  2008-06-13       Impact factor: 5.864

7.  Noncompliance in neurologic patients.

Authors:  David B Weiss; Thomas P Beresford; Robert M House
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.972

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.